Product Description
MAN-01 facilitates the drainage of liquid through the Schlemm's Canal; the testing on mice has consistently delivered positive results in relieving IOP for patient with primary open angle glaucoma. (Sourced from: https://qbiomed.com/pipeline/man-01)
Mechanisms of Action: ANG Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Q BioMed
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Glaucoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|